How the comparison of Age-related Macular Degeneration Treatments Trial results will impact clinical care

American Journal of Ophthalmology

Volumn 152, Issue 4, 2011, Pages 509-514

  Davis, Janet ^a   Olsen, Timothy W ^b   Stewart, Michael ^c   Sternberg Jr , Paul ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTIBIOTIC AGENT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRAP EYE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VERTEPORFIN;

ALLERGIC REACTION; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; CEREBELLUM INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMORBIDITY; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG PACKAGING; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; ENDOPHTHALMITIS; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE; HEART ARREST; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; INFECTION RISK; MEDICARE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSEUDOENDOPHTHALMITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VOMITING;

EID: 80053328390     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2011.07.004     Document Type: Article

References (35)

1. D.F. Martin, M.G. Maguire, G.S. Ying CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
2. R.J. Brechner, P.J. Rosenfeld, J.D. Babish, and S. Caplan Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare Fee-For-Service Part B claims file Am J Ophthalmol 151 5 2011 887 895.e1
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trialsTAP Report Arch Ophthalmol 117 10 1999 1329 1345
4. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr, M. Feinsod, D.R. Guyer VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 27 2004 2805 2816 (Pubitemid 40051904)
5. S. Michels, P.J. Rosenfeld, C.A. Puliafito, E.N. Marcus, and A.S. Venkatraman Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study Ophthalmology 112 6 2005 1035 1047 (Pubitemid 40797459)
6. P.J. Rosenfeld, A.A. Moshfeghi, and C.A. Puliafito Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 4 2005 331 335 (Pubitemid 41073112)
7. A.A. Moshfeghi, P.J. Rosenfeld, and C.A. Puliafito Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study Ophthalmology 113 2006 2002 2011
8. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431 (Pubitemid 44511557)
9. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444 (Pubitemid 44511558)
10. S. Aisenbrey, F. Ziemssen, and M. Völker Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 245 7 2007 941 948 (Pubitemid 46979534)
11. R.L. Avery, D.J. Pieramici, M.D. Rabena, A.A. Castellarin, M.A. Nasir, and M.J. Giust Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 3 2006 363 372.e5
12. Z.F. Bashshur, A. Bazarbachi, A. Schakal, Z.A. Haddad, D.P. El Haibi, and B.N. Noureddin Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 142 1 2006 1 9 (Pubitemid 43946791)
13. R.M. Rich, P.J. Rosenfeld, and C.A. Puliafito Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Retina 26 5 2006 495 511 (Pubitemid 44620390)
14. R.F. Spaide, K. Laud, and H.F. Fine Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 4 2006 383 390 (Pubitemid 44197628)
15. R. Lazic, and N. Gabric Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 245 1 2007 68 73 (Pubitemid 46766732)
16. A.J. Augustin, S. Puls, and I. Offermann Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone Retina 27 2 2007 133 140
17. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 8 2006 859 870 (Pubitemid 44547437)
18. R. Steinbrook The price of sightranibizumab, bevacizumab, and the treatment of macular degeneration N Engl J Med 355 14 2006 1409 1412 (Pubitemid 44511554)
19. J. Mordenti, R.A. Cuthbertson, and N. Ferrara Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration Toxicol Pathol 27 5 1999 536 544 (Pubitemid 29446822)
20. M. Kozloff, M.U. Yood, J. Berlin Investigators of the BRiTE study Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study Oncologist 14 9 2009 862 870
21. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 17 2002 11393 11398 (Pubitemid 34920936)
22. M.W. Stewart, and P.J. Rosenfeld Predicted biological activity of intravitreal VEGF Trap Br J Ophthalmol 92 5 2008 667 668 (Pubitemid 351684178)
23. Q.D. Nguyen, S.M. Shah, and D.J. Browning A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration Ophthalmology 116 11 2009 2141 2148.e1
24. S.R. Sadda, G. Stoller, D.S. Boyer, B.A. Blodi, H. Shapiro, and T. Ianchulev Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year ANCHOR study Retina 30 9 2010 1390 1399
25. C. Campa, R. Hagan, and J.N. Sahni Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration Invest Ophthalmol Vis Sci 52 6 2011 3446 3451
26. B. Gupta, T. Adewoyin, S.K. Patel, and S. Sivaprasad Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration Br J Ophthalmol 95 3 2011 386 390
27. H. Oubraham, S.Y. Cohen, and S. Samimi Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 1 2011 26 30
28. C.D. Regillo, D.M. Brown, and P. Abraham Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2 2008 239 248
29. U. Schmidt-Erfurth, B. Eldem, R. Guymer EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 5 2011 831 839
30. Supplement to: The CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration Adverse Events by System Organ Class, Preferred Term, and Treatment Group, Severity 2 or higher, as of December 31, 2010 pp 6566 and 7778 http://www.nejm.org/doi/suppl/10.1056/NEJMoa1102673/ suppl-file/nejmoa1102673-appendix.pdf Accessed May 15, 2011
31. Lucentis™ Package Insert, Genentech Corporation ©2008 Genentech, Inc. So. San Francisco, CA www.lucentis.com/lucentis/pdf/prescribing- information.pdf Accessed May 15, 2011
32. P. Abraham, H. Yue, and L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 Am J Ophthalmol 150 3 2010 315 324.e1
33. B.P. Nicholson, and A.P. Schachat A review of clinical trials of anti-VEGF agents for diabetic retinopathy Graefes Arch Clin Exp Ophthalmol 248 7 2010 915 930
34. C. Schmucker, C. Ehlken, L.L. Hansen, G. Antes, H.T. Agostini, and M. Lelgemann Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review Curr Opin Ophthalmol 21 3 2010 218 226
35. L.S. Lim, G. Cheung, and T.Y. Wong The ABC trial: more questions than answers [letter] BMJ 2011 Forthcoming